2210010N04Rik Inhibitors
Chemical inhibitors of the protein 2210010N04Rik employ various methods to disrupt its function. Dasatinib targets multiple tyrosine kinases, including BCR-ABL and Src family kinases, which are essential for the phosphorylation events that activate numerous proteins, including 2210010N04Rik. By inhibiting these kinases, Dasatinib can prevent the activation of 2210010N04Rik, disrupting its role in the cell. Similarly, AZD0530 and Bosutinib, both Src family kinase inhibitors, and PP2, a selective inhibitor of the same group, work to obstruct the activation or regulation of 2210010N04Rik by these kinases. Palbociclib, by selectively inhibiting CDK4 and CDK6, obstructs the cell cycle progression, which is closely linked to the regulation of various proteins, including 2210010N04Rik, thus indirectly inhibiting its function by halting cellular processes that rely on proper cell cycle progression.
Erlotinib, targeting the EGFR tyrosine kinase, can impede the signaling cascades that may result in the activation of 2210010N04Rik. Inhibition of EGFR by Erlotinib stops the downstream signaling required for the function of many proteins involved in these pathways. Rapamycin, an mTOR inhibitor, by suppressing the mTOR pathway, can block the activation of proteins that are part of cell growth and proliferation processes, in which 2210010N04Rik might be involved. Sorafenib, with its multi-kinase inhibition properties, targets RAF, VEGFR, and PDGFR, kinases that could be upstream regulators of 2210010N04Rik in various signaling pathways, thus preventing the protein from being functionally active. Sunitinib, inhibiting receptor tyrosine kinases like PDGFR and VEGFR, can also lead to the functional inhibition of 2210010N04Rik by blocking angiogenic and growth signaling. PF-562271, by inhibiting FAK, can alter cell adhesion and motility processes, thereby potentially inhibiting the function of 2210010N04Rik if it is involved in these cellular functions. Finally, LY294002, a PI3K inhibitor, can impede signaling pathways where PI3K is a central player, which may include pathways regulating the activity of 2210010N04Rik.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a kinase inhibitor that targets multiple tyrosine kinases including BCR-ABL and Src family kinases. 2210010N04Rik is known to be influenced by Src family kinase signaling, and the inhibition of these kinases by Dasatinib can lead to the functional downregulation of 2210010N04Rik by obstructing its activation or interaction with other signaling molecules downstream of Src kinases. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Since 2210010N04Rik is regulated by the cell cycle, Palbociclib can inhibit the protein's function by disrupting the cell cycle progression and in turn, its associated cellular processes, which could include the activity of 2210010N04Rik. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Given that 2210010N04Rik is part of signaling pathways that may be influenced by EGFR signaling, the inhibition of EGFR by Erlotinib can lead to the downstream functional inhibition of 2210010N04Rik by blocking the signaling cascades that would normally result in its activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor which can inhibit the function of 2210010N04Rik through the mTOR signaling pathway. By inhibiting mTOR, it can prevent the activation of downstream proteins that are involved in cell growth and proliferation, processes that 2210010N04Rik may be involved in. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor with targets that include RAF, VEGFR, and PDGFR. As 2210010N04Rik may be part of the RAF and subsequent MAPK signaling pathway, the inhibition of these kinases can lead to the functional inhibition of 2210010N04Rik by blocking the signaling events that would normally activate it or mediate its effects on the cell. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor, which has targets including PDGFR and VEGFR. By inhibiting these kinases, Sunitinib can functionally inhibit 2210010N04Rik by blocking angiogenic and growth signaling pathways in which 2210010N04Rik may play a role. | ||||||
Saracatinib | 379231-04-6 | sc-364607 sc-364607A | 10 mg 200 mg | $115.00 $1056.00 | 7 | |
AZD0530 is a Src family kinase inhibitor. Since 2210010N04Rik may be influenced by Src family kinase pathways, inhibition of these kinases by AZD0530 can result in the functional inhibition of 2210010N04Rik by hindering its activation or involvement in downstream signaling pathways mediated by Src kinases. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. By inhibiting Src family kinases, PP2 can functionally inhibit 2210010N04Rik by obstructing the signaling pathways in which Src kinases activate or regulate the function of 2210010N04Rik. | ||||||